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Background: Diabetic macular edema (DME) is one of the manifestations of diabetic 
retinopathy leading to loss of central vision and visual acuity. It manifests itself with swelling 
around the central part of the retina, the area responsible for sharp vision. Current treatment 
includes laser therapy and intravitreal steroids with preventative measures including diabetes 
control. No one treatment has guaranteed control of diabetic macular edema which leads to 
deteriorating visual acuity, function and quality of life in patients. Vascular endothelial growth 
factor (VEGF) has been shown to be a critical stimulus in the pathogenesis of macular edema 
secondary to diabetes.1 Antiangiogenic therapy encompassed treatment with anti-VEGF which 
inhibits VEGF-driven neovascularization hence macular edema leading to decreased visual 
acuity.
Objective: For this review, we evaluated the effectiveness of intravitreal anti-VEGF in treat-
ing DME.
Data sources: We identified five trials (n = 525) using electronic databases (Cochrane Central 
Register of Controlled Trials [Central], Medline®, and Excerpta Medica Database [EMBASE®]) 
in October 2008, supplemented by hand searching of reference lists, review articles, and con-
ference abstracts.
Methods: We included all randomized clinical trials (RCTs) evaluating any form of intravitreal 
anti-VEGF for treating DME. The main outcome factor was change in best-corrected visual 
acuity and central macular thickness. One author assessed eligibility, methodological quality, 
and extracted data. Meta analysis was performed when appropriate.
Results: We included three trials of adequate methodological quality in our meta-
analysis. Patients treated with anti-VEGF showed improvement in visual acuity of -0.17 
(95% confidence interval [CI]: -0.23, -0.10) and central macular thickness -84.69 (95% CI: 
-117.09, -52.30). Patients treated with combined anti-VEGF and intravitreal triamcinolone 
showed improvement of visual acuity of -0.19 (95% CI: -0.27, -0.11) and central macular 
thickness mean change being –111.20 (95% CI: -148.13, -74.28).
Conclusions: Anti-VEGF has been associated with an improvement in visual acuity and central 
macular thickness in the analysis, however trial analysis was of a short duration and further 
research is needed to determine long-term benefits.
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Introduction
Diabetic macular edema (DME) is one of the manifestations of diabetic retinopathy 
leading to loss of central vision and visual acuity.2 DME results from microvascular 
changes in the retina in both type 1 and type 2 diabetes mellitus.3 DME is defined as 
thickening located within two disc diameters of the center of the macula. When this is Clinical Ophthalmology 2010:4 494
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present within or close to the central macula, it is termed clini-
cally significant macular edema (CSME).4 DME is further 
classified descriptively into focal and diffuse DME. Focal 
DME describes the edema from individual microaneurysms 
where as diffuse DME implies extensive or generalized 
leakage from the posterior capillary bed and breakdown of 
the inner blood–retinal barrier. Combinations of the two are 
frequent.
It is important to detect DME in the assessment of diabetic 
retinopathy as this is the most frequent cause of decreased 
vision from retinopathy. Both macular edema (ME) and 
CSME, defined by proximity of these signs to the foveal 
center, are best assessed using slit-lamp biomicroscopy or by 
grading stereoscopic macular photographs. Optical coherence 
tomography (OCT) may be also used to provide valuable 
confirmation and quantification of the clinical grading for 
DME and facilitate monitoring of its response to therapy.4
This review is concerned with diabetic macular edema, 
both focal and diffuse. The treatment considered in this 
review is anti-vascular endothelial growth factor (anti-
VEGF).
Epidemiology
Between 25% and 44% of people with diabetes have some 
form of diabetic retinopathy (DR) at any point in time. 
The United States National Eye Institute pooled data from 
eight well-conducted population-based studies of persons 
aged 40 years or older with consistent retinopathy grading 
from retinal photographs. Data included that from five United 
States (US) studies, one West Indian study, and two Australian 
studies (Blue Mountains Eye Study [BMES] and Melbourne 
Visual Impairment Project [MVIP]). The overall crude DR 
prevalence was 40%. The prevalence of sight-threatening 
retinopathy (CSME or proliferative diabetic retinopathy 
[PDR]) was 8.2%. The general US population prevalence of 
DR and sight-threatening retinopathy were 3.4% (4.1 million 
persons) and 0.8% (900,000 persons), respectively. Projected 
to the current Australian population, these rates suggest a 
prevalence of 300,000 and 65,000, respectively, for any DR 
and sight-threatening retinopathy (PDR or CSME) in persons 
aged over 40 years.4
Clinical presentation and diagnosis
Blurred vision is the most common clinical presentation of 
DME, as well as distortion of the visual image (metamor-
phopsia), floaters, and changes in contrast sensitivity. Photo-
phobia, changes in color vision, and scotoma occurs in DME 
while a loss of vision is associated with increased severity 
and progression of the disease. Chronic macular edema can 
be associated with cystoid macular edema.
Stereoscopic observation of the macular is considered the 
most acceptable way to diagnose DME, however use of OCT, 
stereofundus photography and fluorescein angiography have 
become acceptable tools for diagnosis in clinical practice.5
Treatment options
Strict glycemic control is the hallmark of prevention and 
halts progression of disease. Laser photocoagulation is used 
to coagulate tissue either by direct focal photocoagulation for 
focal macular edema or using grid photocoagulation for dif-
fuse DME. The Early Treatment Diabetic Retinopathy Study 
(ETDRS) demonstrated that photocoagulation reduced the 
risk of moderate vision loss, especially for those eyes with 
macular edema that involved or threatened the center of the 
macular.6 This has become a standard treatment in clinical 
practice. Steroids including intravitreal triamcinolone (IVT) 
or surgical implantation have increased in popularity for 
treatment of DME due to their angiostatic effects and anti-
permeabilty properties which minimize systemic toxicity. 
Vitrectomy is considered for treatment in eyes with chronic 
or diffuse DME that is not responsive to laser.7
Pathophysiology and intervention
Vascular endothelial growth factor (VEGF); also known 
as VEGF-A) has an important role in angiogenesis (ie, the 
migration and mitosis of endothelial cells) up-regulating 
methane monooxygenase and αvβ3 activity, and the creation 
of blood vessel lumen and fenestrations. As seen in preclini-
cal models, VEGF has been shown to facilitate survival of 
existing vessels, contribute to vascular abnormalities (eg, 
tortuousness and hyper permeability) that may impede 
effective delivery of antitumor compounds, and stimulate 
new vessel growth.8
VEGF has been shown to be an endothelial cell specific 
mitogen, an angiogenic inducer, and is also known to increase 
retinal vessel permeability.2 Hypoxia-regulated VEGF release 
likely plays a key role in the normal development of the 
retina and, given its hypoxia inducibility, VEGF became 
an attractive candidate as a mediator of pathological intra-
ocular neovascularization. Expression of VEGF messenger 
ribonucleic acid (mRNA) spatially and temporally correlates 
with neovascularization in several animal models of retinal 
ischemia.33 Elevations of VEGF levels in the aqueous and 
vitreous humor of human eyes with proliferative retinopa-
thy secondary to diabetes, and other conditions have been 
  previously described.9Clinical Ophthalmology 2010:4 495
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Anti-VEGF modalities have been shown to potently 
  suppress angiogenesis and growth in a variety of human 
tumor cells lines and also to inhibit neovascularization of 
ischemic retinal disease.
Bevacizumab is a full-length humanized monoclonal 
antibody against VEGF10 meaning it binds to all subtypes 
of VEGF. Pegaptanib is a synthesized anti-VEGF aptamer 
of a single ribonucleic acid strand that specifically targets 
VEGF-165 and binds only to it. Aptamers are oligonucle-
otide ligands that are selected for high-affinity binding to 
molecular targets.11 Ranibizumab (rhuFab-VEGF) is an 
antibody fragment which neutralizes all VEGF isoforms and 
bioactive fragments.
Recent studies have demonstrated the usefulness of 
anti-VEGF in the reduction of macular edema secondary 
to central retinal vein occlusion, vascular permeability, and 
fibrovascular proliferation in retinal neovascularization sec-
ondary to PDR, and choroidal neovascularization secondary 
to aged-related macular degeneration (AMD).12
Rationale for a systematic review
Monoclonal antibodies against vascular endothelial growth 
factor (VEGF) were first developed in treatment of meta-
static colorectal cancer.13 Anti-vascular endothelial growth 
factor is now commonly used for age-related macular 
degeneration to halt progression of abnormal growth of 
blood vessels in the back of the eye. A Cochrane review of 
five RCTs concluded the use of two anti-VEGFs to reduce 
the risk of visual acuity loss in neovascular age-related 
macular degeneration.14 More recently, these results have 
prompted trials in applying anti-VEGF in diabetic macular 
edema and macular edema secondary to central retinal 
vein occlusion.
In a 6-month follow-up study for anatomic and best-
corrected visual (BCVA) acuity after primary intravitreal 
bevacizumab (Avastin®) in patients with DME, Arevalo et al2 
showed improvements in visual acuity, OCT, and fluorescan 
angiography (FA) for all doses injected. Nguyen et al1 showed 
promising results with ranibizumab (a specific antagonist of 
VEGF) in a nonrandomized clinical trial. Results showed 
intraocular injections of ranibizumab significantly reduced 
foveal thickness and improved visual acuity in 10 patients 
with DME.
In a retrospective review Chung et al15 concluded a 
decrease in mean visual acuity score after three months in an 
ischemic subgroup (patients with an enlarged foveal avascular 
zone [FAZ] or broken perifoveal capillary ring at the border 
of the FAZ, with a distinct area of capillary nonperfusion). 
Their findings indicate the use of anti-VEGF has a negative 
effect on short-term visual outcome in a particular subgroup 
of DME.
DME continues to progress in spite of a lack of a gold 
standard treatment, although options of vitrectomy, laser 
photocoagulation, and the emerging popularity of intravitreal 
steroids have been shown to halt progression of disease.
Although the ETDRS demonstrated that immediate focal 
photocoagulation reduced moderate visual loss by 50% 
(from 24% to 12%, 3 years after initiation of treatment), 
12% of treated eyes still lost 15 ETDRS letters at 3 year 
follow-up. Approximately 40% of treated eyes with retinal 
thickening involving the center of the macula at baseline 
still had thickening involving the center at 12 months. Only 
3% of laser-treated eyes experienced a gain of 3 lines 
of vision.6
Anti-VEGF provides an option to treatment for these 
patients and it may also be a very useful adjunctive treat-
ment before laser or vitrectomy surgery or a potentially 
important role as an adjunct to laser in the management of 
DME. Recently, RCTs have been published and continued 
to examine various antiangiogenic therapies. There has been 
no systematic review published evaluating RCTs conducted 
with treatment of VEGF for DME. Given the disease burden 
and significance of vision in terms of quality of life, a sys-
tematic review is needed to examine the evidence regarding 
the effectiveness and safety of antiangiogenic therapy with 
anti-VEGF modalities for treatment of DME.
Objective
The objective of this review was to assess the effectiveness 
of antiangiogenic therapy with anti-VEGF modalities in the 
treatment of diabetic macular edema. Tables 1 and 2 show 
inclusion and exclusion criteria for the studies considered 
for this review.
Data sources
We searched the Cochrane Central Register of Controlled 
Trials (Central) (which contains the Cochrane Eyes and 
Vision Group Trials Register) in the Cochrane Library, 
Medline® and EMBASE®. There were no language or data 
restrictions in the search for trials. The databases were last 
searched on October 9, 2008. Reference lists of included 
trials were searched. The Australian National Health and 
Medical Research Council (NHMRC) guidelines for diabetic 
retinopathy references were searched. Archives of Oph-
thalmology, Ophthalmology, Retina, and the New England 
Journal of Medicine were searched for clinical trials and Clinical Ophthalmology 2010:4 496
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reviews. Hand-searching of references and their associated 
clinical trials was conducted.
We also searched for unpublished clinical trials and 
those in progress using clinical trials repositories including 
the National Institute of Health repository,16 the Current 
Controlled Trials repository,17 and the National Research 
Register Repository.18 Authors were contacted of unpub-
lished closed trials for initial results. For full search details, 
see Appendix.
Selection of studies
Screening of titles and abstracts resulting from electronic 
and manual searches were reviewed. Abstracts were classi-
fied as relevant, potentially relevant, or not relevant for this 
review. Full copies of abstracts were obtained for relevant 
and potentially relevant reviews. Abstracts and full reviews 
were read to determine inclusion. Only randomized clinical 
trials were eligible. Study findings are in concordance with 
the Quorom statement. Figure 1 illustrates this selection of 
studies with a flow diagram.
Methods
Data extraction and management
Table 3 illustrates extracted data for the primary and second-
ary outcomes for this review.
Data synthesis
BCVA and central macular thickness (CMT), the primary 
outcome variables, are expressed as continuous variables. 
Standard deviations were calculated by Cunningham 
et al using actual P values obtained from t-tests quoted by 
Cochrane.19
For every study, we calculated the mean difference for the 
primary outcome BCVA, LogMAR, and the CMT using 95% 
confidence intervals. The outcome measures were pooled by 
use of the fixed-effect model as there were only three trials 
used in the meta-analysis.
Heterogeneity was calculated using Cochran’s Q statis-
tic and quantified using the I2 statistic. These indicated the 
proportion of variability across studies due to heterogeneity, 
rather than sample error. Despite a high I2, results were pooled 
as examination of these studies on a forest plot indicated that 
the individual trial results were consistent in the direction of 
the effect (ie, the mean difference and confidence intervals 
largely fell on one side of the null line).
Clinical heterogeneity was present between the studies 
in relation to dosage and type of anti-VEGF use. Treatment 
duration and follow-up varied from 12 to 36 weeks. Despite 
clinical heterogeneity, trials were pooled and overall efficacy 
from any type of dose or duration of anti-VEGF was assessed 
in the objectives. Subgroup analysis was not performed due 
to the limited trials. Characteristics of age, gender ratios, 
and baseline visual acuity were similar across all trials, 
Table 1 Inclusion criteria for considering studies for this review
Types of studies Randomized controlled trials
Participants We included trials that have enrolled 
  participants of any age and sex with any type 
of DME (focal or diffuse), as diagnosed in the 
included studies.
Interventions We included trials that compared any  
anti-VEGF of any dose and duration. This 
was compared with another treatment, sham 
treatment, or no treatment.
Outcome measures Primary outcome: BCVA: the difference in 
BCVA as continuous data (converted in 
  LogMAR). 
One or more lines of improvement from 
baseline (ETDRS, Snellen or LogMAR 
equivalent). 
Central macular thickness: retinal thickness 
from baseline as measured by ocular coher-
ence tomography.5
Secondary outcomes Anatomical measures: One or more grade 
reduction of macular edema. Presence of 
edema via direct fundoscopy. Fluorescein 
angiography leakage.
Adverse effects Ocular hypertension
Anterior chamber reaction Lens opacity 
progression (cataract formation)
Endophthalmitis and inflammation Fibrous 
proliferation 
Iris or retinal neovascularization Reduction in 
visual acuity and blindness 
Death
Quality of life measures No data
Economic data No data
Abbreviations: BCVA, best-corrected visual acuity; DME, diabetic macular edema; 
anti-VEGF, anti-vascular endothelial growth factor; ETDRS, Early Treatment Diabetic 
Retinopathy Study.
Table 2 Exclusion criteria for considering studies for this review
Exclusion criteria 
 
 
 
 
RCTs for interventions of VEGF for diabetic 
retinopathy with no mention of diabetic macular 
edema or clinically significant diabetic macular 
edema were excluded in the analysis.
Studies of macular edema due to another cause 
other than DME were excluded.
Full text was reviewed and discussed.
Studies that were not RCT.
Abbreviations: RCT, randomized clinical trials; VEGF, vascular endothelial growth 
factor; DME, diabetic macular edema.Clinical Ophthalmology 2010:4 497
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28 abstracts reviewed 
279 potentially 
relevant references 
screened
5 randomized clinical 
trials included
15 full-text studies 
reviewed
Excluded because they were 
irrelevant: topic, animal studies, 
duplicates 
Excluded duplicate studies reviews and 
discussions  
Diabetic retinopathy trials with no mention 
of diabetic macular edema were excluded 
in the analysis, but later discussed 
Excluded duplicate studies, case 
reports, and observational studies 
Figure 1 Selection of studies flow diagram.
however variability in trial quality and intervention type, 
dose, and timing of administration varied. Table 4 highlights 
the characteristics of the included studies.
Asymmetry assessment of the funnel plot was not con-
ducted for publication bias as only three trials were used in 
the final analysis. In future analyses, asymmetry of the fun-
nel plot will be used to identify publication bias if at least 
seven studies are used. In the case of missing data, efforts 
to contact authors were made. Data was entered in Review 
Manager 5 (Cochrane, Sanfrancisco, CA) and fixed effect 
models were used.
Assessment of risk of bias in included studies has 
been considered using methods described in chapter 6 
of the Cochrane Handbook for Systematic Reviews of 
Interventions.19 The following parameters were assessed: 
randomization process, allocation concealment, and mask-
ing of participants and investigators. Table 4 offers a sum-
mary of included studies characteristics for trial quality 
  assessment score.
Description of studies
Electronic searches conducted in July 2008 and October 
2008 resulted in 279 abstracts with 28 abstracts reviewed. 
Of those, 15 full-texts were read and five were found to 
meet our eligibility criteria. The reference list of each of the 
15 full-text articles was searched for other relevant articles. 
Nine studies were excluded. Table 4 provides a summary 
of included studies characteristics and the Appendix lists 
included and excluded studies. Eight publications were not 
RCTs and one did not mention DME with an intervention of 
vitrectomy surgery in the assessment and primary outcome 
measure.
To our knowledge, there are 10 ongoing clinical tri-
als using anti-VEGF for treatment of DME. Authors and 
trial groups were contacted, but we were unable to obtain 
  preliminary data. Cunningham et al21 was funded by a 
  pharmaceutical company (Pfizer).
Participants
We included five studies from three countries (United States, 
Iran, and Brazil) with a total of 525 eyes represented in the 
review. The range of eye enrollments in the trials varied 
with the largest study enrolling 172 eyes,21 however this 
was a study with three intervention groups and one control 
group. The numbers of subjects within each group, therefore, 
become smaller (n = 42–44). The study by Paccola et al24 was 
the smallest trial, enrolling 28 eyes.
Participants were male and female adults. All studies 
excluded patients who had undergone previous laser treat-
ment at least 3–6 months prior. Soheilian et al23 included 
patients without prior laser treatment, whereas Ahmadieh 
et al20 and Paccola et al24 included participants unresponsive 
to previous macula laser photocoagulation at least 3 months 
prior. The studies by both Scott et al22 and Cunningham et al21 
included patients who had had no laser treatment within 3 
and 6 months, respectively.
No study included patients with other ocular conditions 
affecting assessment and progression of Visual acuity, such 
as central retinal vein occlusion, uveitis, or recent cataract 
surgery. All trials included patients with clinically significant Clinical Ophthalmology 2010:4 498
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macular edema and generally defined the edema as focal or 
diffuse and as persistent or refractory. All trials mentioned 
diabetic macular edema. None of the trials mention whether 
the patients also had cystic macular edema.
All of the trials explicitly report the primary outcome fac-
tor of BCVA according to the ETDRS. CMT is reported in all 
the studies either at baseline to follow-up measurements or as 
a mean change in thickness, measured in µm. Duration of dia-
betes and baseline intraocular pressure (IOP) measurements 
were not explicitly mentioned in all the trials. Adverse events 
were described within trials. Scott et al22 presented safety 
summary data on adverse event rates between groups, while 
Ahmadieh et al20 and Soheilian et al23 described percent-
ages of adverse reaction rates amongst the different groups. 
Cunningham et al21 listed adverse events among their subjects 
with pooled results for certain subgroups (eg, hypertension). 
Two-way analysis of variance was performed by Paccola 
et al24 for raised IOP and description of adverse effects. 
Adverse events described were tabled see table of adverse 
events but data for analysis was not performed.
Interventions
Ahmadieh et al20 was a three arm trial comparing intravitreal 
becavizumab (IVB) to IVB intravitreal triamcinolone 
acetonide (IVT) to sham. Cunningham et al21 compared 
three doses of IVB to sham. The Scott et al22 study was a 
5 treatment-arm trial divided as follows: a) focal laser at 
baseline with no intervention; b) 1.25 mg of IVB; c) 2.5 mg of 
IVB; d) baseline IVB and sham; e) and 1.25 mg of IVB plus 
laser therapy. The Soheilian et al23 study was a three-arm trial 
comparing IVB and IVB/IVT to macular photocoagulation. 
Paccola et al24 compared IVB to IVT interventions.
Bevacizumab was employed in four studies and one study 
used pegaptanib. No studies were included using ranibizumab. 
Table 4 gives a summary of included studies characteristics.
Outcome measures
All trials considered visual acuity using ETDRS charts and 
CMT using OCT as their major outcome. Definitions of visual 
acuity varied across the trials. BCVA was quantified in all 
trials. All trials used OCT to measure CMT in µm, however 
some studies reported CMT change whilst others reported 
mean baseline and follow-up results. CMT was quantified 
in all trials.
Adverse events of interest included: IOP increase 
reported in five trials; anterior chamber reaction reported 
in three trials; nil progression of leno pacification reported 
in all trials; iris neovascularization reported in three trials; 
Table 3 Extracted data
Participant characteristics Total number
Gender
Age
Country
Type of diabetic macular edema
Diagnostic criteria
Baseline visual acuity or changed in BCVA
Visual fields
Fluorescein angiography
OCT-determined thickness of diabetic 
macular edema
Patient inclusion and exclusion criteria
Intervention Agent
Dose
Timing of first dose in relation to diagnosis
Delivery route
Frequency and treatment length
Study and methodology Study design
Trial identifiers
Study size
Randomization
Masking, allocation concealment
Duration of each study
Primary outcomes BCVA
Change in visual acuity
OCT
Secondary outcomes Retinal thickness from baseline as 
  measured by OCT5
Anatomical measures:
Presence of edema via direct fundoscopy
Fluorescein angiography leakage
Adverse effects:
Ocular and systemic toxicity
Ocular hypertension
Anterior chamber reaction
Lens opacity progression
Endophthalmitis
Blindness
Additional data Economic data, quality of life data
Treatment compliance and losses to  
follow-up
Missing data Authors contacted
Data has been entered in Review  
  Manager 5
Fixed effect models used
Data collection Microsoft Excel® spreadsheet
Abbreviations: BCVA, best-corrected visual acuity; OCT, optical coherence 
tomography.Clinical Ophthalmology 2010:4 499
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and endophthalmitis, which was considered in all trialsm 
but only reported as events in two trials. There was no data 
on blindness or loss of color vision. General adverse events 
such as hypertension, thromboembolic events, and death 
were reported in four trials.
Methodological quality
Overall, three of the trials’20–22 assessors were adequately 
masked. Intravitreal injections were masked in one23 and there 
was masking for the measurement via OCT and fluorescein 
angiography in the other.24 The fundus assessments were 
performed by two retina specialists who were aware of the 
treatment assignment. Study data were collected, interpreted, 
and analyzed by two other masked investigators. Intention-
to-treat analysis was performed in three trials.20,21,23
Randomization consisted of varying length of permuted 
blocks, simple randomization, and applying a dynamic 
minimization procedure using a stochastic treatment alloca-
tion algorithm based on a variance method. The process of 
randomization was described in one study,24 but allocation 
concealment was not described in any of the trials.
In the Ahmadieh et al20 study, one patient in the control 
group died during the study period. Cunningham et al21 left 
out nine patients from the study as a result of one death and 
eight patient requests. Scott et al22 had two subjects withdraw 
before completion of the study and their overall visit comple-
tion rate was 93%. Paccola et al24 reported that two subjects 
missed two consecutive treatments, while Soheilian et al23 
reported no losses to follow-up.
Results
Meta-analysis of data was only possible for three trials.20,21,23 
We were unable to use data from one trial,22 as results were 
expressed in medians and interquartile ranges. The authors 
have been contacted for their raw data, including means and 
standard deviations. This trial will be added to the meta-
analysis once appropriate results obtained.
The study by Paccola et al24 was not included in the meta-
analysis as this study compared intravitreal bevacizumab to 
intravitreal triamcinolone instead of a control or standard 
therapy such as laser. The study by Paccola et al24 has been 
included in the qualitative analysis of anti-VEGF.
It should be noted that with respect to the forest plots 
reported in this review, for outcomes such as gain in visual 
acuity and CMT, effect estimates to the right of the vertical 
line favor test treatment.
Anti-VEGF treatments were shown to have a benefit in 
improving BCVA. For instance, Cunningham et al21 compared 
three differing doses of intravitreal pegaptanib compared to 
a control injection. Three forests plots each with a differing 
dose of pegaptanib showed a consistent benefit with the 
intervention on visual acuity. Using pegaptanib 0.3 mg in the 
meta-analysis, the mean change in visual acuity was -0.17 
(95% confidence interval [CI]: -0.23, -0.10). A similar treat-
ment effect was seen using 1 mg and 3 mg of pegaptanib with 
a mean difference of -0.17 (95%  CI: -0.23, -0.10) and -0.14 
(95% CI: -0.20, -0.07), respectively (Figures 2–4).
Anti-VEGF therapy has a benefit on CMT. Cunningham 
et al21 compared three differing doses of intravitreal pegap-
tanib to a control injection. Three forests plots, each demon-
strating a differing dose of pegaptanib, showed a consistent 
benefit of the intervention on CMT. Using pegaptanib 0.3 mg 
in the meta-analysis, the mean change on CMT was found 
to be -84.69 (95% CI: 117.09, -52.30). A similar treatment 
effect was seen using 1mg and 3 mg of IVP with a mean dif-
ference -84.69 (95% CI: -117.09, -52.30) and -72.47 (95% 
CI: -106.67, -38.27) in evidence (Figures 5–7).
Combined anti-VEGF with intravitreal triamcinolone was 
shown to benefit both visual acuity and central macular thick-
ness compared to the control. Mean difference for visual acuity 
Study or subgroup
Ahmadieh et al201.25 mg IVB
Cunningham et al21 0.3 mg IVP
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Total (95% CI)
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Experimental Mean difference Mean difference
IV, fixed, 95% CI
−0.5 −0.25 0 0.25 0.5
Favors experimental Favors control
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Control
Figure 2 Effect of best corrected visual acuity using anti-VEGF (0.3 mg of pegaptanib in one study).
Abbreviations: anti-VEGF, anti-vascular endothelial growth factor; SD, standard deviation; CI, confidence interval; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib.Clinical Ophthalmology 2010:4 501
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Study or subgroup
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37
33
Control
Figure 3 Effect of best-corrected visual acuity using anti-VEGF (1 mg of pegaptanib in one study).
Abbreviations: CI, confidence interval; IV, intravenous; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; SD, standard deviation; VEGF, vascular endothelial growth factor.
Study or subgroup
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Figure 6 Effect for central macular thickness using anti-VEGF (1 mg of pegaptanib in one study).
Abbreviations: CI, confidence interval; IV, intravenous; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; SD, standard deviation; VEGF, vascular endothelial growth factor.
Study or subgroup
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Soheilian 2007 IVB
Total (95% CI)
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Figure 5 Effect of central macular thickness using anti-VEGF (0.3 mg of pegaptanib in one study).
Abbreviations: CI, confidence interval; IV, intravenous; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; SD, standard deviation; VEGF, vascular endothelial growth factor.
Study or subgroup
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Figure 4 Effect of best-corrected visual acuity using anti-VEGF (3 mg of pegaptanib in one study).
Abbreviations: CI, confidence interval; IV, intravenous; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; SD, standard deviation; VEGF, vascular endothelial growth factor.Clinical Ophthalmology 2010:4 502
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Ahmadieh 2007 1.25 mg IVB
Figure 7 Effect of central macular thickness using anti-VEGF (3 mg of pegaptanib in one study).
Abbreviations: CI, confidence interval; IV, intravenous; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; SD, standard deviation; VEGF, vascular endothelial growth factor.
Study or subgroup
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Figure 8 Effect of best-corrected visual acuity using IVB/IVT.
Abbreviations: CI, confidence interval; IV, intravenous; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; SD, standard deviation; VEGF, vascular endothelial growth factor.
was -0.19 (95% CI: -0.27, -0.11) and the CMT mean change 
was -111.20 (95% CI: -148.13, -74.28) (Figures 8 and 9).
Scott et al22 revealed a benefit in central macular thick-
ness when using the intervention of 1.25 mg and 2.5 mg of 
intravitreal bevacizumab compared to the use of laser. There 
was only a trend towards reduction up to 12 weeks, however. 
Visual acuity also improved with the two IVB interventions 
compared to laser at 3 weeks.
There was significant heterogeneity amongst the trials: 
65%–81% for the assessment of visual acuity and 49%–73% 
for CMT. Despite the high I2, results were pooled and 
reported, as examination of the forest plot indicated that the 
individual trial results were consistent in the direction of 
the effect (ie, the mean difference, standard deviation and 
confidence intervals largely fell on the side of the null line 
favoring the intervention).
Subgroup analysis and assessment of publication bias 
could not be preformed due to small study numbers and 
data set. Meta-regression may be preformed in future to 
group the differing interventions in the Cunningham21 and 
Scott22 studies compared to a control group once data becomes 
available.
The pooled trend favors intervention using anti-VEGF to 
increase visual acuity and encourage CMT changes. Further-
more, trial quality was found to be better among those showing 
an improvement of BCVA and CMT using anti-VEGF.
Complications
There were no significant increases in complications reported 
among the interventions trialed. Complications associated 
with intravitreal injections, including ocular hypertension, 
were noted in a few studies. All trials noted to have ocular 
hypertension comment of successful treatment of increased 
IOP. Table 5 shows a summary of included study adverse 
events.
Discussion
In this systematic review of randomized controlled trials our 
meta-analysis has shown that anti-VEGF alone or in com-
bination with triamcinolone is effective in the treatment of 
diabetic macular edema with an improved change in BCVA 
and CMT. Over with the treatment duration ranging from 
12 to 36 weeks the initial analysis has shown a short-term 
benefit for the intervention and available information of 
adverse effects does not suggest potentially vision threaten-
ing complications with intravitreal injections.
Only the three trials included in the meta-analysis were 
of good methodological quality. There is no direct evidence 
comparing different types of anti-VEGF therapies so far 
published. The Scott et al22 trial was conducted by a pharma-
ceutical company, thus has potential for bias due to conflict 
of interest. As mentioned above, we were also unable to use 
this trial in the meta-analysis due to the presentation of data Clinical Ophthalmology 2010:4 503
Anti-VEGF for diabetic macular edema Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
using medians and interquartile ranges. Our assumption was 
that the outcome distributions were skewed.
Cunningham et al21 used three differing doses of IVP 
compared to a control. We were unable to scrutinize these 
interventions together in the same analysis as the same group 
of control subjects would have been entered twice. Hence, 
three separate analysis tables were calculated, each represent-
ing a different dose, from this trial. Future meta-regression 
to pool these groups may be performed.
Paccola et al24 suggest intravitreal triamcinolone has a 
significant benefit in visual acuity over intravitreal bevaci-
zumab. There was also a significant reduction in CMT in the 
intravitreal triamcinolone group at week 24 (P = 0.024), with 
similar results for visual acuity compared with IVB. Analysis 
of IVB was not performed to control so, although a benefit 
was anecdotally noted to improve visual acuity and CMT 
from baseline, this provides no significance statistically.
Subgroup analysis was not performed due to the limited 
number of studies. Similarly, assessment of publication bias 
was not performed due to the limited number of studies 
included in meta-analysis. Future inclusion of more clinical 
trials is needed for meaningful subgroup analysis including 
assessment of publications bias.
Quality of life and economic data were not available in 
any of the included studies making it is difficult to assign 
meaning to LogMAR changes in visual acuity. However, 
the trend is favorable towards intervention with regards 
to improvement of vision and perhaps slowing further 
progression of disease and its associated morbidity. Reduc-
tion in macular thickness, especially in regards to CMT, 
is considered a mechanism for visual improvement in the 
treatment of macular edema. Therefore, a corresponding 
reduction in CMT would be expected if there was a trend 
towards vision improvement. This is confirmed in the 
analysis where the intervention using anti-VEGF favored 
CMT improvement.
As current treatment is directed at stabilizing or reducing 
vision loss, an important finding is that there were no signifi-
cant increases in complications among the interventions.
The results were limited by heterogeneity in the included 
trials. The difference in the intervention doses and duration 
of treatment contributed to this. A strength within the studies 
is that the exact definition and measurement of outcomes were 
fairly consistent and our pooled results should not be biased 
due to misclassification. The limited data for the Scott et al22 
study made it difficult to quantify the trial results concerning 
the effect of the intervention in a meaningful way.
Overall, most studies show a promising trend towards 
benefits in visual acuity and central macular thicken with 
use of anti-VEGF. Excluded studies continue to confirm 
this trend for most patients, although subgroups of patients 
with DME with ischemia were found to have a negative 
outcome.15
Conclusion
Strict glycemic and blood pressure control are still the hall-
marks of prevention and progression of diabetic macular 
edema. The ETDRS brought laser therapy into consideration 
for mainstream use for diabetic macular edema with some 
modest benefit to visual acuity evidenced.6
Anti-VEGF was associated with an improvement in visual 
acuity and CMT in our analysis. Trials studied were all of a 
short duration and there were no long-term follow-up studies 
found. There was no evidence found comparing the different 
types of anti-VEGF. The use of anti-VEGF is promising to 
improve visual acuity and CMT caused by diabetic macular 
edema. Further trials are being conducted, at present, with 
ongoing follow-up studies to assist in determining overall 
long-term benefit. The Appendix outlines some of the 
  characteristics of these ongoing studies.
Implications for future research
The five studies in included in our report dealt primarily 
with persistent or refractory diabetic macular edema and 
raised issues including the duration of intervention, dosage, 
timing of repeats and follow-up, and the role of combina-
tion therapy with intravitreal triamcinolone in relationship to 
control or laser therapy. The question arises whether treatment 
Study or subgroup
Ahmadieh 2007 IVB/IVT
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Total (95% CI)
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−111.20 [−148.13, −74.28]
Mean difference
IV, fixed, 95% CI
−200 −100 0 100 200
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Experimental Control Mean difference
Favors control
Figure 9 Effect of central macular thickness using IVB/IVT.
Abbreviations: CI, confidence interval; IV, intravenous; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; SD, standard deviation; VEGF, vascular endothelial growth factor.Clinical Ophthalmology 2010:4 504
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should be reserved for just this chronic or refractory group 
of patients or introduced during earlier stages of diabetic 
macular edema. Economic and quality of life data need to be 
considered, as well as further quantitative analysis of overall 
effects of complications. Long-term, follow-up studies with 
considerations for adverse effects need to be quantified and 
documented to provide a better understanding of risk benefits 
for patients with diabetic macular edema.
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Table 2 Search: Medline®
  1.  randomized controlled trial.pt.
  2.  (randomized or randomised).ab,ti.
  3.  placebo.ab,ti.
  4.  randomly.ab,ti.
  5.  trial.ab,ti.
  6.  groups.ab,ti.
  7.  dt.fs.
  8.  or/1–7
  9.  exp animals/
10.  exp humans/
11.  9 not (9 and 10)
12.  8 not 11
13.  exp clinical trial/
14.  (clin$ adj3 trial$).tw.
15.  ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
16.  placebo$.tw.
17.  random$.tw.
18.  exp experimental design/
19.  exp control group/
20.  18 or 19 or 16 or 13 or 17 or 15 or 14
21.  angiogenes$.tw.
22.  exp angiogenesis inhibitors/
23. exp angiogenic factor/
24.  endothelial cell growth facto$.tw.
25.  exp vasculotropin/
26.    (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ 
or bevacizumab$).tw.
27.  (anti adj2 VEGF$).tw.
28.  (endothelial adj2 growth adj2 factor$).tw.
29.  exp angiogenesis inducing agents/
30.  27 or 25 or 28 or 21 or 26 or 22 or 24 or 23 or 29
31.  exp diabetic retinopathy/
32.  exp macular edema cystoid/
33.  exp macular degeneration/
34.  (macula$ adj2 edema).tw.
35.  (macula$ adj2 edema).tw.
36.  DME.tw.
37.  DMO.tw.
38.  CME.tw.
39.  CSME.tw.
40.  (macula$ adj2 swell$).tw.
41.  microaneurysm$.tw.
42.  (dilat$ adj2 capillar$).tw.
43.  35 or 33 or 32 or 39 or 40 or 36 or 41 or 42 or 38 or 34 or 37 or 31
44.  30 and 43 and 20
45.  from 44 keep 2, 9, 11–12, 15, 22–23, 27... 28
46.  from 45 keep 1, 3, 5, 7, 9–10, 12... 15
47.  from 46 keep 5, 7–9, 12–15 8
48.  from 47 keep 1–3, 5–6 5
 Appendix
Table 1 Search: Central
  1.    diabetic macular edema.mp. [mp=title, original title, abstract, mesh 
headings, heading words, keyword] 18
  2.    diabetic macula odema.mp. [mp=title, original title, abstract, mesh 
  headings, heading words, keyword] 0
  3.    Diabetic Retinopathy.mp. [mp=title, original title, abstract, mesh 
  headings, heading words, keyword] 843
  4.    macular edema.mp. [mp=title, original title, abstract, mesh headings, 
heading words, keyword] 53
  5.    Macular Edema, Cystoid.mp. [mp=title, original title, abstract, mesh 
headings, heading words, keyword] 74
  6.    Macular Degeneration.mp. [mp=title, original title, abstract, mesh 
  headings, heading words, keyword] 609
  7.    (DME or DMO or CME or CSME).mp. [mp=title, original title, 
abstract, mesh headings, heading words, keyword] 197
  8.    6 or 4 or 1 or 3 or 7 or 2 or 5 1620
  9.    angiogenesis inhibitors.mp. [mp=title, original title, abstract, mesh 
  headings, heading words, keyword] 96
10.    angiogenesis inhibitors.mp. [mp=title, original title, abstract, mesh 
headings, heading words, keyword] 96
11.    endothelial growth factors.mp. [mp=title, original title, abstract, mesh 
headings, heading words, keyword] 68
12.    vascular endothelial growth factors.mp. [mp=title, original title, 
abstract, mesh headings, heading words, keyword] 65
13.    (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ 
or bevacizumab$).tw. 120
14.  (anti adj2 VEGF$).tw.
15.  (endothelial adj2 growth adj2 factor$).tw. 265
16.  (macula$ adj2 swell$).tw. 1
17.  11 or 13 or 10 or 9 or 12 or 15 or 14 414
18.  8 and 17 71
19.  from 18 keep 10, 33, 45, 47, 51, 53–54... 9Clinical Ophthalmology 2010:4 507
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Table 3 Search: Embase®
  1. randomized controlled trial.pt.
  2. (randomized or randomised).ab,ti.
  3. placebo.ab,ti.
  4. randomly.ab,ti.
  5. trial.ab,ti.
  6. groups.ab,ti.
  7. dt.fs.
  8. or/1–7
  9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. clinical trial.pt
14. cluster trial
15. exp control group
16. double blind$.tw
17. single blind$.tw
18. (blind$ or mask$).tw
19. exp cross over
20. exp comparative study
21. prospective$.tw
22. or 13–21
23. or 12–22
24. angiogenes$.tw.
25. exp angiogenesis inhibitors/
26. exp angiogenic factor/
27. endothelial cell growth facto$.tw.
28. exp vasculotropin/
29.   (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ 
or bevacizumab$).tw.
30. (anti adj2 VEGF$).tw.
31. (endothelial adj2 growth adj2 factor$).tw.
32. exp angiogenesis inducing agents/
33. or 24–32
34. exp diabetic retinopathy/
35. exp macular edema cystoid/
36. exp macular degeneration/
37. (macula$ adj2 edema).tw.
38. (macula$ adj2 edema).tw.
39. DME.tw.
40. DMO.tw.
41. CME.tw.
42. CSME.tw.
43. (macula$ adj2 swell$).tw.
44. microaneurysm$.tw.
45. (dilat$ adj2 capillar$).tw.
46. or 34–45
47. 23 and 33 and 46
Characteristics of included studies
Ahmadieh et al20
Title: Intravitreal bevacizumab with or without triamcinolone 
for refractory diabetic macular edema; a placebo-controlled, 
randomized clinical trial
Methods: Study design: RCT
Method of randomization: Using computer generated 
random lists a random block permutation was performed 
with block lengths varying randomly (3,6)
Number of randomized: 115 DME eyes (41 eyes in anti 
IVB arm, 37 eyes in the IVB/IVT arm and 37 eyes in the 
control arm.)
Method of allocation concealment: no data
Outcome assessor masking: Adequately masked
Study duration: 24 weeks
Losses to follow-up: One patient died in the control group 
during the study period.
Intention to treat analysis: performed
Participants: Inclusion criteria: Clinically significant 
macular edema unresponsive to previous macular laser with 
the last session being more than three months prior.
Exclusion criteria: visual acuity 20/40, history of cataract 
surgery within the past 6 months, prior intraocular injection 
or vitrectomy, glaucoma or ocular hypertension, Proliferative 
diabetic retinopathy with high risk characteristics, vitreous 
hemorrhage, significant media opacity and presence and 
traction on the macula. Monocular patients, pregnant 
patients and those with a serum creatinine of 3 mg/100 
were excluded.
Type of DME: CSME
Prior laser treatment: All participants
Age: 59.7 ± 8.3
Comparability of baseline characteristics: groups were 
matched for age, sex, baseline visual acuity, hypertension, 
smoking history, stage of diabetic retinopathy, number of 
previous laser sessions at the macula and history of PRP 
(P  0.05) Treatment group were not matched for CMT 
which was lower in the control group compared to the other 
two groups (P  0.05).
Interventions: Test intervention: IVB 1.25 mg
Test intervention: IVB/IVT (1.25 mg/2 mg)
Control: needleless syringe placed against conjunctiva 
and sclera. Three injections performed at 6-week 
intervals.
Outcomes: Primary outcome: change in CMT compared 
to baseline.
Measurement of primary outcome: CMT by OCTClinical Ophthalmology 2010:4 508
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Secondary outcome: Change in best corrected LogMAR 
visual acuity, IOP rise, cataract progression, intraocular 
inflammation and other serious adverse effects.
Measurement of secondary outcome: VA by ETDRS chart, 
IOP measure by application tonometer.
Notes: Data source: published data
Funding source: Nonindustry funded
Country: Iran
Cunningham et al21
Title: A Phase II randomized double-masked trial of 
pegaptanib, an antivascular endothelial growth factor 
aptamer, for diabetic macular edema
Methods: Study design: RCT
Method of randomization: Dynamic minimization 
procedure using a stochastic treatment allocation algorithm 
based on variance method.
Number of randomized: 172 eyes 44 eyes in the 0.3 mg 
IVP arm, 44 eyes in the 1 mg IVP arm, 42 eyes in the 3 mg 
IVP arm and 42 eyes in the sham arm.
Method of allocation concealment: no data
Outcome assessor masking: Adequately masked
Losses to follow-up: 9 patients discontinued from the study 
(1 death and 8 by request)
Intention to treat analysis: performed
Participants: Inclusion criteria: Demonstrated to 
have macular edema involving the center of the macula 
demonstrated by OCT with corresponding leakage from 
micro aneurysms, retinal telangiectatisis, or both on fluo-
rescein angiography. Best-corrected visual acuity (Snellen 
equivalent) 20/50–20/320. IOP less than 23 mmHg and those 
patients in which focal photocoagulation could be delayed 
for at least 16 weeks safely.
Exclusion criteria: History of panretinal or focal 
photocoagulation within the previous 6 months. Any 
abnormality thought to confound VA assessments or fundus 
photography including cataracts, vitreoretinal traction within 
1 disc diameter of the fovea confirmed either clinically or on 
OCT, vitreous incarceration in a previous wound or incision, 
any retinal vein occlusion involving the macula and atrophy/
scarring/fibrosis or hard exudates involving the center of the 
macula that would preclude improvement in VA. History 
of intraocular surgery within 12 months of the study, active 
ocular infection, serious allergies to fluorescein dye. GHb 
levels of 13%, 2 episodes of ketoacidosis within 1 year, 
severe cardiac disease, clinical significant peripheral vascular 
disease, uncontrolled hypertension, stroke within 1 year and 
previous therapeutic radiation to eye, head, or neck.
Types of DME: Focal and diffuse
Prior laser treatment: Some participants, at least 6 months 
previously
Age: (0.3 mg) 61.9 ± 10.0; (1 mg) 62.8 ± 10.1; (3 mg) 61.3 ± 
9.8; (sham) 64.0 ± 9.3
Intervention: Test intervention: 0.3 mg of IVP, 1 mg IVP, 
3 mg IVP
Control intervention: Sham: needleless syringe pressed 
against the conjunctiva and sclera
Repeat treatments: injections were given at entry, week 6, 
and week 12 for a minimum of three injections. Additional 
injections were administered every 6 weeks up to week 30.
Outcomes: Primary outcome: Best-corrected visual acuity 
and change in CMT compared to baseline.
Measurement of primary outcome: ETDRS chart for VA 
and OCT for CMT
Secondary outcome: Presence of improvement via fluores-
cein angiography, IOP, safety endpoints included all adverse 
events. Vital signs and biochemical analysis of blood and 
urine performed.
Measurement of secondary outcome: Fluorescein angi-
ography, IOP measure by application tonometer, blood and 
urine analysis.
Data source: published data
Funding source: Sponsored by Eyetech Pharmaceuticals. Inc 
New York, New York, and Pfizer Inc®, New York, New York
Country: United States of America
Scott et al22
Title: A Phase II randomized clinical trial of intravitreal 
bevacizumab for diabetic macular edema
Methods: Study design: RCT
Method of randomization: Simple randomization
Number of randomized: 109 eyes included. 19 eyes in the 
laser group, 22 in the 1.25 IVB group, 24 eyes in the 2.5 mg 
IVB group, 22 eyes in the 1.25 mg IVB at baseline group 
and 22 eyes in the 1.25 mg IVB plus laser group.
Method of allocation concealment: No data
Outcome assessor masking: Adequately masked
Losses to follow-up: 2 subjects withdraw before completion. 
Overall visit completion rate was 93%.
Intention to treat analysis: not performed
Participants: Inclusion criteria: Patients were at least over 
18 years of age. Best-corrected electronic ETDRS VA score 
24 (20/320 or better) and 78 (20/32 or worse), defined 
retinal thickening due to DME involving the center of the 
macula based on clinical examination. OCT central subfield Clinical Ophthalmology 2010:4 509
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275 µm and no history of treatment for DME at any time 
within the prior 3 months.
Exclusion criteria: Only one eye included in the study.
Type of DME: retinal thickening due to DME involving the 
center of the macula
Prior laser treatment: no laser treatment within 3 months 
of study starting time.
Age: 65
Intervention: Test intervention: 1.25 mg of IVB at baseline 
and at 6 weeks; 2.5 mg of IVB at baseline and at 6 weeks; 
1.25 mg of IVB at baseline; 1.25 mg of IVB at baseline and 
6 weeks plus photocoagulation at 3 weeks.
Control intervention: Focal photocoagulation at baseline
Outcomes: Primary outcome: best-corrected visual acu-
ity, CMT
Measurement of primary outcome: ETDRS chart for VA 
and OCT for CMT
Secondary outcome: Adverse effects; endophthalmitis, IOP, 
cardiac dysfunction, BP
Measurement of secondary outcome: clinical examination 
and IOP measure by application tonometer
Data source: published data
Funding source: National Eye Institute, Bethesda, Maryland 
and by a grant from the Juvenile Diabetes Research 
Foundation International, New York, New York
Country: United States of America
Soheilian et al23
Title: Intravitreal bevacizumab (Avastin) injection alone or 
combined with triamcinolone versus macular photocoagulation 
as primary treatment of diabetic macular edema
Methods: Study design: RCT
Method of randomization: Random block permutation 
method performed using computer generated random list. 
Block length varied randomly (6, 12).
Number of randomized:103 eyes 37 eyes in the IVB arm, 
33 eyes in the IVB/IVT arm and 33 eyes in the MPC arm.
Method of allocation concealment: No data
Outcome assessor masking: Intravitreal injections were 
masked.
Losses to follow-up: nil
Intention to treat analysis: performed
Participants: Inclusion criteria: clinically significant macu-
lar edema based on the ETDRS definitions.
Exclusion criteria: Previous panretinal or focal laser 
  photocoagulation, prior intraocular injection or operation, 
history of glaucoma or ocular hypertension, visual acuity 
of 20/40 or better or worse than 20/320, presence or iris 
neovascularization, significant media opacity and high risk 
or active diabetic retinopathy. Monocularity, pregnancy and 
  creatinine level 3 mg/dL were excluded.
Types of DME: focal and diffuse
Prior laser treatment: no
Age: 62.4 ± 6.1
Intervention: Test intervention: 1.25 mg IVB; 1.25 mg 
IVT; 2 mg IVT
Control intervention: macular laser photocoagulation
Repeat treatment: no
Outcomes: Primary outcome: Change in best-corrected 
visual acuity (LogMAR), CMT changes
Measurement of primary outcome: VA by ETDRS chart, 
OCT for CMT
Secondary outcome: Changes in fluorescein angiography 
  leakage, ocular hypertension, anterior chamber reaction and 
lens opacity progression.
Measurement of secondary outcome: leakage assessed 
by fluorescein angiography, IOP measure by application 
tonometer and clinical examination performed.
Data source: published data
Funding source: Ophthalmic Research Centre of Shaeed 
Beheshti Medical University Tehran Iran
Country: Iran
Paccola et al24
Title: Intravitreal triamcinolone versus bevacizumab for 
treatment of refractory diabetic macular edema (IBEME) 
study
Methods: Study design: RCT
Method of randomization: no data
Number of randomized: 28 eyes randomized 13 eyes IVB 
arm 13 eyes in IVT arm two losses
Method of allocation concealment: no data
Outcome assessor masking: Adequately masked for 
OCT, fluorescein angiography and fundus assessment 
were performed by two retina specialists who were aware 
of the treatment assignment. Study data were collected 
and interpreted and analyzed by two other masked 
investigators.
Losses to follow-up: two patients missed two consecutive 
treatments
Intention to treat analysis: not performed
Participants: Inclusion criteria: Refractory DME (defined 
herein as the presence of clinically significant macula edema 
as per ETDRS criteria by biomicroscopic evaluation which 
had persisted despite at least one session of macula laser 
photocoagulation performed at least 3 months earlier). Clinical Ophthalmology 2010:4 510
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Patients to have diffuse fluorescein leakage involving the 
foveal center and most of the macula area. A (LogMAR) 
ETDRS BCVA of 0.3 (20/40) or worse and a CMT greater 
than 300 µm on OCT.
Exclusion criteria: Aphakic or pseudophakic eyes, 
glycosylated hemoglobin (HBA1c) level above 10%, 
history of glaucoma or ocular hypertension defined by a 
pressure higher than 22 mmHg. An ocular condition other 
than diabetes that may effect or alter the visual acuity 
during the study example retinal vein occlusion, uveitis, 
neovascular glaucoma or other inflammatory disease. 
Patients with a history of a thromboembolic event (MI 
or CVA) or major surgery within the past 6 months were 
excluded. Controlled HT, known coagulation abnormali-
ties or current use of anticoagulative medications other 
than aspirin or any condition affecting follow-up or 
documentation.
Types of DME: refractory diffuse or focal DME
Prior laser treatment: all participants
Age: 65.58 (8.44) IVB, 67.08 (4.67) IVT
Intervention: Test intervention: 1.5 mg IVB
Control intervention: 4 mg of IVT
Repeat treatment: no
Outcomes: Primary outcome: change in best visual acuity 
(LogMAR), CMT changes.
Measurement of primary outcome: VA by ETDRS chart, 
OCT for CMT
Secondary outcome: IOP, cataract progression, and 
systemic adverse effects.
Measurement of secondary outcome: IOP measure by 
application tonometer, dilated slit lamp biomicroscopic 
examination, indirect fundus examination, color fundus 
photography, and fluorescein angiography performed.
Data source: published data
Funding source: Conselho Nacional de Desenvolvimento 
Cientiffico e Tecnologico (CNPq)
Country: Brazil
Characteristics of excluded studies
Rizzo et al25
Title: Injection of intravitreal bevacizumab (Avastin) as a pre-
operative adjunct before vitrectomy surgery in the treatment of 
severe Proliferative diabetic retinopathy (PDR)
Methods: Study design: RCT
Method of randomization: Random numbers list used in 
order to assign group 1 or 2.
Number randomized: 22 patients 11 eyes with preoperative 
IVB 11 patients no intervention.
Method of allocation concealment: no data
Outcome assessor masking: no
Losses to follow-up: none
Intention to treat analysis: performed
Participants: Inclusion criteria: tractional retinal 
detachment, tractional-rhegmatogenous retinal detachment 
or tractional detachment complicated with vitreous 
hemorrhage.
Exclusion criteria: History of vitrectomy in the study eye, 
history of thromoboembolic events (including MI or CVA), 
major surgery within the last 3 months or planned in the 
next 28 days, uncontrolled hypertension, known coagulation 
abnormalities or currently or use of anticoagulative 
medication other than aspirin.
Types of DME: not given; patient diagnosed with 
proliferative diabetic retinopathy.
Prior laser treatment: unknown
Age: 52
Intervention test: IVB 1.25 mg
Control intervention: No intervention
Outcomes: Primary outcome: feasibility of the surgery
Measurement of primary outcome: duration of surgery, 
average number of tools exchanged during surgery: number 
of blunt or sharp dissections, intraoperative bleeding, 
frequency of endodiatermy, and number of intraoperative 
breaks.
Secondary outcome: visual and anatomically outcome at 
6 months
Measurement of secondary outcome: ophthalmological 
exam including BCVA slit-lamp examination, retinal 
fluorescein angiography, and blood pressure measurement.
Data source: published data
Funding source: not given
Country: Italy
Reason for exclusion: Participant has severe proliferative 
diabetic retinopathy. No mention of diabetic macular edema. 
Patient’s further intervention includes vitrectomy surgery.
Nguyen et al26
Title: Vascular endothelial growth factor is a critical stimulus 
for diabetic macular edema
Methods: Study design: nonrandomized clinical trial
Method of randomization: not randomized
Number of patients: 10
Method of allocation concealment: none
Outcome assessor masking: none
Losses to follow-up: none
Intention to treat analysis: N/AClinical Ophthalmology 2010:4 511
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Participants: Inclusion criteria: 18 years or older, VA 
between 20/40 and 20/320, a foveal thickness by OCT of 
250 µm or greater, serum HbA1c  6% for 12 months before 
randomization, no potential contributing causes to reduce 
visual acuity other than DME and a reasonable expectation 
that photocoagulation would not be required for the next 
six months.
Prior laser treatment: not specified
Age: 60
Intervention: Test intervention: IVR 0.5 mg at baseline, 
1, 2, 4 and 6 months.
Control intervention: no control
Outcomes: Primary outcome: Foveal thickness
Measurement of primary outcome: OCT
Secondary outcome: Macular volume and VA
Measurement of secondary outcome: macular volume 
measured by OCT and VA that was measured by protocol 
of the ETDRS.
Data source: published data
Funding source: The Wilmer Eye Institute, The Johns 
Hopkins University School of Medicine, and Baltimore 
Maryland. Innovative Grant Award from the juvenile Diabetes 
Research Foundation by a scholarship from the scientific and 
technological Research Council of Turkey (S.T) and by a K23 
Career Development Award from the National Eye Institute. 
Drug provided by Genentech, Inc.
Country: United States of America
Reason for exclusion: Nonrandomized clinical trial.
Arevalo et al27
Title: Primary intravitreal bevacizumab (Avastin) for diabetic 
macular edema. Results from the Pan-American Collabora-
tive Retina Study Group at 6 month follow-up
Methods: Study design: retrospective review
Method of randomization: N/A
Number of randomization: N/A
Number studied: 110 eyes reviewed, 78 eyes with follow-up 
of 6 months
Method of allocation concealment: N/A
Outcome assessor masking: N/A
Losses to follow-up: 32 eyes with less than 6-month 
follow-up
Intention to treat analysis: N/A
Participants: Inclusion criteria: Patients treated with at 
least one injection of IVB 1.25 mg or 2.5 mg.
Exclusion criteria: Patients with DME previously treated 
with laser photocoagulation or IVT. Patients with macular 
ischemia and the presence of an epiretinal membrane or 
vitreomacular traction syndrome. Patients with uncontrolled 
hypertension and recent thromboembolic event.
Types of DME: all
Prior laser treatment: no
Age: 59.7 ± 9.3
Intervention: Test intervention: IVB 1.25 mg and 2.5 mg
Control intervention: N/A
Repeat treatment: second injection
Outcomes: Primary outcome: changes in BCVA, CMT, 
and angioscopy changes
Measurement of primary outcome: ETDRS VA, OCT, 
fluorescein angiography.
Secondary outcome: adverse effects
Measurement of secondary outcome: ophthalmoscopic 
examination, fluorescein angiography, IOP measure by 
application tonometer.
Data source: published data
Funding source: Supported in part by the Arevalo-Coutinho 
  Foundation for Research in Ophthalmology, Caracas, 
Venezuela.
Country: Venezuela, Mexico, Costa Rica, and Brazil
Reason for exclusion: nonrandomized clinical trial.
Chung et al15
Title: Effects of macular ischemia on the outcome of 
intravitreal bevacizumab therapy for diabetic macular 
edema
Methods: Study design: retrospective review
Method of randomization: N/A
Number of randomization: N/A
Number studied: 59 eyes of 53 patients
Method of allocation concealment: N/A
Outcome assessor masking: adequate masking
Losses to follow-up: N/A
Intention to treat analysis: N/A
Participants: Inclusion criteria: clinically significant DME 
  according to ETDRS study, a minimum follow-up time of 
3 months and recent fluorescein angiography within two 
weeks before treatment. All three criteria needed to be met.
Exclusion criteria: intraocular surgery, including cataract 
  extraction, laser treatments including panretinal photoco-
agulation, posterior capsulotomy, or focal/grid macular 
photocoagulation, within 6 months before the treatment 
and the presence of comorbid ocular conditions that might 
affect VA.
Type of DME: CSME
Prior laser treatment: greater than 6 months previously
Age: ischemic group 65, nonischemic group 63.4Clinical Ophthalmology 2010:4 512
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Intervention: Test intervention: 1.25 mg IVB
Control intervention: N/A
Repeat treatment: 1 months 3 months
Outcomes:  Primary  outcome:  BCVA  and  foveal 
thickness
Measurement of primary outcome: ETDRS scores for VA 
and OCT for foveal thickness.
Secondary outcome: injection complications, leakage
Measurement of secondary outcome: IOP measure by 
application tonometer and fluorescein angiography for 
assessment of leakage.
Data source: published data
Funding source: Department of Ophthalmology, NHIC Ilsan 
Hospital, Gyounggido, Korea; and The Institute of Vision 
Research, Department of Ophthalmology,  Yonsei University 
College of Medicine, Seoul, Korea
Country: Korea
Reason for exclusion: nonrandomized clinical trial.
Byeon et al28
Title: Short-term results of intravitreal bevacizumab for 
macular edema with retinal vein obstruction and diabetic 
macular edema
Methods: Study design: retrospective review
Method of randomization: N/A
Number of randomization: N/A
Number studied: 39 eyes studied 25 eyes with DME 
studied
Method of allocation concealment: N/A
Outcome assessor masking: N/A
Losses to follow-up: N/A
Intention to treat analysis: N/A
Participants: Inclusion criteria: macula edema caused by 
central (CRVO) or branched retinal vein occlusion (BRVO), 
or DR, and on the basis of ME severity involving the foveal 
center and/or a failure to respond to other treatments. 
Bevacizumab administration commenced at least 3 months 
after cessation of previous treatments.
Exclusion criteria: Patients with ocular trauma, inflammation, 
surgery within the previous 3 months, or glaucoma or ocular 
hypertension were excluded. In addition, patients with 
uncontrolled hypertension, cerebrovascular accidents or 
ischemic cardiovascular disease were excluded.
Types of DME: all
Prior laser treatment: greater than 3 months previously
Age: 62.5 ± 10.7 in patients with DME
Intervention: Test intervention: 1.25 mg IVB
Control intervention: N/A
Repeat treatment: Yes
Outcomes: Primary outcome: LogMAR visual acuity and 
central retinal thickness (CRT).
Measurement of primary outcome: ETDRS chart 
(LogMAR) for VA and OCT for CRT.
Secondary outcome: IOP, changes in macula edema, and 
leakage.
Measurement of secondary outcome: Measurement of IOP 
by tonometer, slit-lamp evaluation and fundus examination, 
and fluorescein angiography
Data source: published data
Funding source: Institute of Vision Research
Department of Ophthalmology Yonsei University College 
of Medicine 134 Shinchon-Dong Seodaemun-Gu, Seoul 
Korea
Country: Korea
Reason for exclusion: nonrandomized clinical trial.
Yanyali et al29
Title: Bevacizumab (Avastin) for diabetic macular edema in 
previously vitrectomized eyes
Methods: Study design: Retrospective, non comparative, 
interventional case series.
Method of randomization: N/A
Number of randomization: N/A
Number studied: 10 eyes
Method of allocation concealment: N/A
Outcome assessor masking: N/A
Losses to follow-up: N/A
Intention to treat analysis: N/A
Participants: Inclusion criteria: persistent DME despite 
prior pars plana vitrectomy with internal limiting membrane 
removal.
Exclusion criteria: With only focal macular edema attributable 
to focal leaks from micro aneurysms, treated with macular laser 
  photocoagulation within six months, treated with panretinal 
photocoagulation within 12 months, with traction retinal 
detachment, with active neovascularization, with media opac-
ity such as cataract or vitreous hemorrhage, with evidence of 
epiretinal membrane shown by fundus examination and OCT 
(Stratus III OCT; Carl Zeiss, Dublin, California, USA), treated 
with PPV and ILM removal within 12 months, and underwent 
cataract extraction within six months. Patients with chronic 
renal failure maintained with renal dialysis were excluded 
from the study as well.
Types of DME: all
Prior laser treatment: previous 12 months
Age: 62 ± 8Clinical Ophthalmology 2010:4 513
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Intervention: Test intervention: 1.25 mg IVB
Control intervention: N/A
Repeat treatment: all eyes given 3 injections of IVB
Outcomes: Primary outcome: Foveal thickness and 
BCVA
Measurement of primary outcome: OCT to measure foveal 
thickness and ETDRS chart for VA
Secondary outcome: no data
Measurement of secondary outcome: no data
Data source: published data
Funding source: N/A
Country: Turkey
Reason for exclusion: nonrandomized clinical trial. Patient’s 
previous vitrectomy performed.
Shimura et al30
Title: Comparative therapy evaluation of intravitreal 
bevacizumab and triamcinolone acetonide on persistent dif-
fuse diabetic edema
Methods: Study design: prospective comparative interven-
tional case series
Method of randomization: N/A
Number of randomization: N/A
Number studied: 28 eyes of 14 patients. In each patient one 
eyes received IVB and the other eyes received IVT.
Method of allocation concealment: N/A
Losses to follow-up: 2 patients dropped out for personal 
reasons
Intention to treat analysis: not performed
Participants: Inclusion criteria: patients with bilateral 
DME whose foveal thickness was more than 400 µm and 
who had a visual acuity of resolution (LogMAR) 0.3 in 
both eyes.
Exclusion criteria: previous therapy for macular edema 
including grid laser treatment (within 12 months of study start), 
intravitreal injection of any drugs or vitrectomy surgery.
Types of DME: diffuse and focal
Prior laser treatment: 12 months prior
Age: 65.7
Intervention: Test intervention: One eye 1.25 mg IVB other 
eye 4 mg IVT
Repeat treatment: No
Outcomes:  Primary  outcome:  BCVA  and  foveal 
thickness
Measurement of primary outcome: ETDRS chart for VA 
and OCT for foveal thickness
Secondary outcome: IOP and diffuse leakage around 
fovea
Measurement of secondary outcome: leakage assessed by 
fluorescein angiography
Data source: published data
Funding source: Department of Ophthalmology, NTT East 
Japan Tohoku Hospital, Sendai, Miyagi, Japan Department 
of Ophthalmology and Visual Science, Tohoku University 
Graduate School of Medicine, Sendai, Miyagi, Japan 
Shiono Eye Center, Sendai, Miyagi, Japan Department of 
Ophthalmology, Fukushima Medical University, School of 
Medicine, Fukushima, Japan Department of Ophthalmology, 
Kagoshima University, Graduate School of Medical and 
Dental Sciences, Kagoshima, Japan.
Country: Japan
Reason for exclusion: nonrandomized clinical trial.
Haritoglou et al31
Title: Intravitreal bevacizumab (Avastin) therapy for 
persistent diffuse diabetic macula edema
Methods: Study design: prospective, consecutive, 
noncomparative case series
Method of randomization: N/A
Number of randomization: N/A
Number studied: 51 patients 51 eyes studied with IVB
Method of allocation concealment: N/A
Outcome assessor masking: N/A
Losses to follow-up: all patients completed 6 weeks of 
follow-up; 23 (45%) completed 12 weeks of follow-up. 
Sixteen patients (70%) had received at least two intravitreal 
injections
Intention to treat analysis: not performed
Participants: Inclusion criteria: patients with diffuse, 
clinically significant diabetic macular edema who did not 
respond to other treatments such as photocoagulation, 
intravitreal injection of triamcinolone, or vitrectomy. Patients 
were included in the study independently of the size of the 
leakage area, retinal thickness (as determined by optical 
coherence tomography [OCT]), visual acuity, age, metabolic 
control, type of diabetes mellitus, or previous treatments such 
as photocoagulation, vitrectomy, or intravitreal triamcinolone 
injection performed beyond a 6-month period previously.
Types of DME: all
Prior laser treatment: all participants
Age: 64.1
Intervention: Test intervention IVB
Control intervention: N/A
Repeat treatment: 16 patients had 2 injections of IVB
Outcomes:  Primary  outcome:  BCVA  and  retinal 
thicknessClinical Ophthalmology 2010:4 514
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Measurement of primary outcome: VA by Snellen testing 
and ETDRS standard charts at a 4 m distance retinal thick-
ness measurement by OCT
Secondary outcome: IOP and fundus changes
Measurement of secondary outcome: IOP measurement 
device, slit-lamp examination, and stereoscopic biomicros-
copy of the retina using a 78-diopter lens
Data source: published data
Funding source: From the Department of Ophthalmology, 
Ludwig-Maximilians-University, Munich, Germany.
Country: Germany
Reason for exclusion: nonrandomized clinical trial.
Chun et al32
Title: A pilot study of multiple intravitreal injections of 
ranibizumab in patients with center-involving clinically 
significant diabetic macular edema
Methods: Study design: single-center, open-label, dose-
escalating pilot study
Method of randomization: N/A
Number of randomization: N/A
Number studied: 10 eyes
Method of allocation concealment: N/A
Outcome assessor masking: N/A
Losses to follow-up: Nil
Intention to treat analysis: Not performed
Participants: Inclusion criteria: patients over 18 years 
of age (male or female) with a history of diabetes mellitus 
who showed stereo fundus photographic evidence of center-
involving clinically significant DME in the study eye within 
28 days of the start of the study. Patients able to defer laser 
treatment for over 4 months.
Exclusion criteria: exclusively small 100 µm at the 
maximum dimension focal areas of edema in the study 
eye, central macular damage likely to preclude improve-
ment in visual acuity (VA), previous use of intraocular 
steroids, previous participation in another study of antian-
giogenic drugs, other ocular disorders that may confound 
interpretation of study results, ocular inflammation in 
the study eye, and history of vitreoretinal surgery in the 
study eye.
Type of DME: CSME
Age: 65.6 in 0.3 mg IVR group and 73.0 in 0.5 mg IVR 
group
Intervention: Test intervention: 0.3 mg or 0.5 mg of 
ranibizumab
Control intervention: N/A
Repeat treatment: 1 and 2 months
Outcomes:  Primary  outcome:  BCVA  and  retinal 
thickness
Measurement of primary outcome: VA measured by 
ETDRS standard and retinal thickness measurement by 
OCT
Secondary outcome: macula leakage, drug tolerability.
Measurement of secondary outcome: fluorescein angiog-
raphy (FA) to determine macular leakage, patients’ measures 
and withdrawal measured tolerability.
Data source: published data
Funding source: Ophthalmic Consultants of Boston, 
Boston, Massachusetts. New England Eye Center, Tufts–New 
England Medical Center, Boston, Massachusetts. Genentech, 
Inc., South San Francisco, California. Dr Heier is a member 
of the Genentech Lucentis Advisory Board.
Country: United States of America
Unpublished ongoing studies
Reason for exclusion: nonrandomized clinical trial.
Characteristics of ongoing studies
Kriechbaum
Title: A randomized, double-masked study with Intra-
ocular bevacizumab (Avastin®) compared with intraocular 
triamcinolone (Volon A®) in patients with clinical significant 
diabetic macular edema
Method: randomized double blind trial
Intervention: 2.5 mg IVB compared to 8 mg IVT
Inclusion criteria: patients with diabetic macular edema 
with center involvement of CMT (macular edema) of at 
least 300 microns in the central subfield as measured by 
OCT; best-corrected visual acuity, using ETDRS charts, 
of 20/25 to 20/400 (Snellen equivalent) in the study eye; 
patients with decrease in vision in the study eye due to 
foveal thickening from diabetic macular edema and not to 
other causes, in the opinion of the investigator; patients 
without a necessity for panretinal laser photocoagulation 
for at least 3 months after study inclusion
Exclusion criteria: a condition that would preclude a 
patient for participation in the study in opinion of investiga-
tor, eg, unstable medical status including glycemic control 
and blood pressure. History of systemic corticosteroids 
within 3 months prior to randomization or topical, rectal, 
or inhaled corticosteroids in current use more than 3 times 
per week.
Prior/concomitant treatment: macular laser photoco-
agulation, panretinal laser photocoagulation within the 
past 3 months, previous treatment with intravitreal or 
sub-Tenon triamcinolone within the past 3 months in the Clinical Ophthalmology 2010:4 515
Anti-VEGF for diabetic macular edema Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
study eye, previous participation in clinical trial involving 
antiangiogenic drugs (pegaptanib sodium, ranibizumab, 
anecortave acetate, protein kinase C inhibitor, etc), his-
tory of submacular surgery or other surgical intervention 
for diabetic macular edema in the study eye diabetic 
retinopathy characteristics, high risk proliferative diabetic 
retinopathy in the study eye without complete panretinal 
lasercoagulation and having a risk for intravitreal bleeding, 
concurrent ocular conditions, active intraocular inflam-
mation (grade trace or above) in either eye, vitreomacular 
traction in the study eye evident by OCT, ocular disorders 
in the study eye including retinal vascular occlusion, retinal 
detachment, macular hole, choroidal neovascularization, 
intraocular surgery (including cataract surgery, YAG laser 
capsulotomy) in the study eye within 3 months preceding 
Day 0, uncontrolled glaucoma in the study eye (defined 
as IOP 25 mmHg despite treatment with antiglaucoma 
medication), history of glaucoma filtration surgery, corneal 
transplantation in the study eye concurrent systemic con-
ditions, history of myocardial infarction (in anamnesis or 
signs in ECG), history of congestive heart failure, history 
of stroke or transient ischemic attacks, significant abnor-
malities on laboratory testing (signs on failure of kidney, 
liver disease), premenopausal women not using adequate 
contraception and pregnant or nursing women and history 
of other disease, metabolic dysfunction, physical examina-
tion finding, or clinical laboratory finding giving reasonable 
suspicion of a disease or condition that contraindicates the 
use an investigational drug or that might affect interpreta-
tion of the results of the study or render the subject at high 
risk for treatment complications.
Primary outcome measure: BCVA and CMT
Secondary measures: structural mechanisms of DME by 
fluorescein angiography.
Data source: online clinical trials.gov register
Funding source: Medical University of Vienna
Country: Austria
Jorge
Title: Intravitreal bevacizumab versus intravitreal 
triamcinolone acetonide for refractory diabetic macular 
edema
Methods: randomized controlled trial
Intervention: 2.5 mg IVB compared to IVT 4 mg
Inclusion criteria: refractory diffuse DME (defined herein 
as clinically significant DME (by biomicroscopic evalu-
ation) unresponsive to focal laser photocoagulation (per-
formed at least 3 months before evaluation) and generalized 
breakdown of the inner blood-retina barrier with diffuse 
fluorescein leakage involving the foveal center and most 
of the macular area on fluorescein angiography), and Snel-
len logarithm of minimum angle of resolution (LogMAR) 
BCVA equivalent of 20/40 or worse, and CMT greater than 
300 µm on OCT.
Exclusion criteria: aphakic or pseudophakic eyes, 
glycosylated hemoglobin (HbA1C) rate above 10%, 
history of glaucoma or ocular hypertension, loss of vision 
as a result of other causes, systemic corticoid therapy, 
history of thromboembolic event (including myocardial 
infarction or cerebral vascular accident), major surgery 
within the prior 6 months or planned within the next 
28 days, uncontrolled hypertension (according to guide-
lines of the seventh report of the joint National Commit-
tee on prevention, detection, evaluation, and treatment of 
high blood pressure, 16 known coagulation abnormalities 
or current use of anticoagulative medication other than 
aspirin, severe systemic disease.
Primary outcome: BCVA and CMT by OCT
Secondary outcome: IOP
Data source: online clinical trials.gov register
Funding source: University of Sao Paulo
Country: Brazil
Novartis
Title: A randomized, double-masked, multicenter, Phase II 
study assessing the safety and efficacy of two concentrations 
of ranibizumab (intravitreal injections) compared with 
nontreatment control for the treatment of diabetic macular 
edema with center involvement
Method: treatment, randomized, double-bnlind, placebo 
control, parallel assignment, safety/efficacy study.
Inclusion criteria: diabetic macular edema with center 
involvement in at least one eye, Type 1 or type 2 diabetes 
mellitus diagnosed 2 years prior to screening, and laser 
photocoagulation in the study eye can be withheld for at least 
3 months after randomization.
Exclusion criteria: patients with uncontrolled systemic or 
ocular diseases, have any history of any intraocular surgery 
in the study eye within the past 6 months preceding screening 
and conditions that require chronic concomitant therapy with 
systemic or topical ocular corticosteroids.
Primary outcome measure: no data
Secondary outcome measure: no data
Data source: online clinical trials.gov register
Funding source: Novartis
Country: SwitzerlandClinical Ophthalmology 2010:4 516
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Belfort
Title: A randomized, parallel group, masked clinical study 
to evaluate the efficacy of triamcinolone and bevacizumab 
through intravitreal injection with individual or simultaneous 
drugs to treatment of diabetic macular edema
Method: randomized, double blind (subject, investigator), 
active control, parallel assignment, efficacy study
Intervention: three arm trial a) 1.25 mg IVB b) 4 mg IVT 
c) 1.25 mg IVB and 4 mg IVT
Inclusion criteria: 18 years of age at least, diagnosis of 
diabetes mellitus type 1 or type 2. any one of the following 
will be considered to be sufficient evidence that diabetes 
is present: current regular use of insulin for the treatment 
of diabetes or current regular use of oral hypoglycemic 
agents for the treatment of diabetes or diabetes as defined 
by American Diabetes Association (ADA) or symptoms of 
diabetes (polyuria, polydipsia, and unexplained weight loss) 
or eigth-hour fasting plasma glucose 126 mg/dL. Diabetic 
macular edema clinically observable associated with diabetic 
retinopathy: without prior foveal treatment with laser therapy, 
if photocoagulation or peripherical or macular laser, at least 
3 months or absence of macular ischemia by fluorescein 
angiography on baseline visit. BCVA score between 20 letters 
(20/400 ETDRS) e 70 letters (20/40 ETDRS) in the study eye 
measured by the ETDRS method at qualification/baseline 
visit. Retinal thickness 275 µm by OCT. One eye per patient 
will be chosen for the study. In case of both eye eligible, it 
will be chosen an eye to be treated with study medication and 
another eye treated with laser and taught hyaloid syndrome.
Exclusion criteria: Uncontrolled systemic disease, initiation 
of medical therapy for diabetes or a change from oral 
hypoglycemic agents to insulin therapy within 4 months 
prior to the qualification visit. Renal failure requiring 
hemodialysis or peritoneal dialysis within 6 months prior to 
the qualification visit or any ocular condition in the study 
eye that in the opinion of the investigator would prevent a 
2 lines improvement of visual acuity (eg, severe macular 
ischemia). Presence of branch retinal vein occlusion, central 
retinal vein occlusion, uveitis, pseudophakic cystoid edema 
or any other condition in the study eye which could be 
contributing to macular edema or presence of an epiretinal 
membrane in the study eye. History of IOP elevation in 
response to steroid treatment in either eye or glaucoma or 
optic nerve head change consistent with glaucoma damage. 
Ocular hypertension requiring more than one antiglaucoma 
medication to maintain IOP 11 mmhg at qualification visit, 
presence of anterior chamber intraocular lens in the study eye, 
active optic disc or retinal neovascularization in the study 
eye at qualification visit or active or history of choroidal 
neovascularization in the study eye.
Primary outcome: visual acuity
Secondary outcome: CRT by OCT and tonometry
Data source: clinical trials.gov register
Funding source: Federal University of Sao Paulo
Country: Brazil
Adriana Solís-Vivanco
Title: The efficacy of a single intravitreal injection of 
bevacizumab in patients with diffuse diabetic macular 
edema
Method: treatment, nonrandomized, open-label, uncontrolled, 
single group assignment, safety/efficacy study
Inclusion criteria: Type 2 diabetes, macular edema involving 
the center of the macula demonstrated on OCT, Clear ocular 
media, untreated patients, older than 45 years and BCVA of 
the fellow eye at least 20/100.
Exclusion criteria: Renal diabetic disease, uncontrolled 
hypertension or stroke history, other ocular disease, ocular 
surgery excepting uncomplicated phacoemulsification, his-
tory of photocoagulation (panretinal or focal), and a history 
of another intravitreal treatment (like triamcinolone).
Primary  outcome  measures:  BCVA,  fluorescein 
angiography, and optical coherence tomography
Data source: online clinical trials.gov register
Funding source: Asociacion para Evitar Ia Ceguera en 
Mexico
Country: Mexico
Ute Wolf-Schnurrbusch
Title: Short-term effects of intravitreal bevacizumab and 
triamcinolone in patients with diabetic macular edema
Method: observational
Study design: prospective case control
Participants: Inclusion criteria: patients with clinically 
significant macular edema
Exclusion criteria: retinal thickness 250 µm
Primary outcome measure: central retinal thickness
Secondary outcome: BCVA
Data source: online clinical trials.gov register
Funding source: University Hospital Inselspital, Berne
Country: Switzerland
Sheidow
Title: Effect of Macugen® (pegaptanib) on surgical outcomes 
and growth factors including vascular endothelial growth 
factor (VEGF) levels in patients with proliferative diabetic Clinical Ophthalmology 2010:4
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retinopathy (PDR) and clinically significant diabetic macular 
edema (CSDME)
Method: nonrandomized, controlled trial
Intervention: 0.3 mg of pegaptanib
Inclusion criteria: 18 years or older, type 1 or 2 diabetes, 
patients requiring surgical intervention for complications of 
proliferative diabetic retinopathy with vitreous hemorrhage 
or traction retinal detachment or clinically significant macular 
edema and women postmenopausal for 12 months before the 
study, surgically sterile, or not pregnant, and on effective 
contraception.
Exclusion criteria: previous retinal vein occlusion, any 
intraocular surgery within the previous 12 months, myopia 
of  or = to 8 diopters, and active ocular or periocular 
infection.
Primary outcome: levels of intravitreal Macugen post-
injection of intravitreal Macugen.
Secondary outcome: Effect on ease of surgery post injection 
of intravitreal Macugen.
Data source: online clinical trials.gov register
Funding source: Pfizer®
Country: United Kingdom
Lim
Title: Avastin in the treatment of macular edema and 
uveitis
Method: nonrandomized trial
Intervention: 1.25 mg IVB
Inclusion criteria: Clinically significant macular edema 
secondary to diabetes involving the fovea in one or both 
eyes that has been refractory to previous standard treatments 
(eg, laser) where local steroid therapy is contraindicated 
(eg, pre-existing glaucoma or steroid responder) or 
ineffective, OR 3. Uveitic cystoid macular edema in one 
or both eyes that has either been unresponsive to standard 
treatment (including intravitreal triamcinolone) or where 
further local steroid treatment is relatively contraindicated 
(eg, pre-existing glaucoma or steroid responder) or 
ineffective, OR 4. Subfoveal or juxtafoveal choroidal neo-
vascularization (CNV) secondary to uveitis in one or both 
eyes, best-corrected visual acuity in the affected eye(s) = 
6/12 or worse 5. Subjects must have signed the informed 
consent form.
Exclusion criteria: Loss of vision due to other causes 
(eg, myopic macular degeneration), surgical intervention 
in the study eye within 2 months preceding recruitment, 
significant macular ischemia, no useful vision in fellow 
eye, known allergies to bevacizumab or ranibizumab, active 
ocular infection (eg, conjunctivitis, keratitis), intercurrent 
severe disease such as septicaemia, history of other systemic 
disease(s) that, in the opinion of the investigator, may render 
the subject at a high risk for treatment complications, any 
condition which would affect follow-up or photographic 
documentation (eg, geographical, psycho-social, media 
opacities), unwillingness or inability to give informed 
consent, under age 18, pregnant or lactating women, and 
premenopausal women.
Primary outcome: best-corrected, Early Treatment Diabetic 
Retinopathy Study (ETDRS), visual acuity
Secondary outcome: CMT as measured on OCT
Data source: Australian New Zealand Trials Registry
Funding source: Royal Victorian Eye and Ear Hospital
Country: Australia